Liquidia (LQDA) Stock Price, News & Analysis

Company Overview

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Key Stats

• Today's Range: $15.47 to $15.77
• 50-Day Range: $12.14 to $16.52
• 52-Week Range: $8.26 to $16.81
• Volume: 676,229 shs
• Average Volume: 931,979 shs
• Market Capitalization: $1.33 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.63
• Consensus Rating: Buy

Liquidia Stock Analysis - MarketRank™

Liquidia scored higher than 51% of companies evaluated by MarketBeat, and ranked 568th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Liquidia has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Liquidia has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Liquidia are expected to grow in the coming year, from ($1.51) to ($1.32) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Liquidia is -9.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Liquidia is -9.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Liquidia has a P/B Ratio of 21.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.05% of the float of Liquidia has been sold short.

Short Interest Ratio / Days to Cover

Liquidia has a short interest ratio ("days to cover") of 12.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Liquidia has recently increased by 0.54%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Liquidia does not currently pay a dividend.

Dividend Growth

Liquidia does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

19.05% of the float of Liquidia has been sold short.

Short Interest Ratio / Days to Cover

Liquidia has a short interest ratio ("days to cover") of 12.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Liquidia has recently increased by 0.54%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.55

News Sentiment

Liquidia has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 44 news articles for Liquidia this week, compared to 5 articles on an average week.

MarketBeat Follows

1 people have added Liquidia to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Liquidia insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $843,326.00 in company stock.

Percentage Held by Insiders

30.10% of the stock of Liquidia is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

64.54% of the stock of Liquidia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LQDA Stock Analysis - Frequently Asked Questions

How have LQDA shares performed this year?

Liquidia's stock was trading at $11.76 at the start of the year. Since then, LQDA stock has increased by 32.7% and is now trading at $15.60.
View the best growth stocks for 2025 here.

How were Liquidia's earnings last quarter?

Liquidia Co. (NASDAQ:LQDA) released its quarterly earnings data on Wednesday, March, 19th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by $0.08. The business earned $2.92 million during the quarter, compared to analyst estimates of $4.60 million. Liquidia had a negative trailing twelve-month return on equity of 163.21% and a negative net margin of 765.38%.

When did Liquidia IPO?

Liquidia (LQDA) raised $50 million in an IPO on Thursday, July 26th 2018. The company issued 4,500,000 shares at $10.00-$12.00 per share. Jefferies and Cowen acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

Who are Liquidia's major shareholders?

Liquidia's top institutional investors include Vanguard Group Inc. (4.20%), Findell Capital Management LLC (3.64%), LM Advisors LLC (2.61%) and Whitefort Capital Management LP (2.35%). Insiders that own company stock include Caligan Partners Lp, Roger Jeffs, Russell Schundler, Michael Kaseta, Rajeev Saggar, Robert A Lippe, Jason Adair and Scott Moomaw.
View institutional ownership trends.

How do I buy shares of Liquidia?

Shares of LQDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Liquidia own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Liquidia investors own include JPMorgan Chase & Co. (JPM), NVIDIA (NVDA), Ford Motor (F), Predictive Oncology (POAI), Tesla (TSLA), Advanced Micro Devices (AMD) and Abbott Laboratories (ABT).

Company Calendar

• Last Earnings: 3/19/2025
• Today: 3/26/2025
• Next Earnings (Estimated): 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:LQDA
• CIK: 1819576
• Web: www.liquidia.com
• Phone: (919) 328-4400
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $26.63
• High Stock Price Target: $34.00
• Low Stock Price Target: $20.00
• Potential Upside/Downside: +70.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.11
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.67)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-78,500,000.00
• Net Margins: -765.38%
• Pretax Margin: -765.38%
• Return on Equity: -163.21%
• Return on Assets: -67.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.33
• Quick Ratio: 6.33

Sales & Book Value

• Annual Sales: $14.00 million
• Price / Sales: 95.07
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.73 per share
• Price / Book: 21.37

Miscellaneous

• Outstanding Shares: 85,299,000
• Free Float: 59,161,000
• Market Cap: $1.33 billion
• Optionable: Optionable
• Beta: 0.07